Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded by Wall Street Zen to Strong-Buy Rating

Key Points

• Wall Street Zen upgraded Regeneron Pharmaceuticals to “strong-buy” from “buy.” Across analysts, the stock has a consensus “Moderate Buy” rating and an average price target of $802.18.
• Regeneron reported strong quarterly results, with earnings of $14.29 per share versus the $10.16 estimate and revenue of $4.29 billion versus the $3.82 billion consensus. Revenue increased 16.7% year over year.
• Shares opened at $784.85, while institutional investors owned 83.31% of the company. Insiders sold 4,146 shares worth approximately $3.43 million over the prior 90 days, through pre-arranged trading plans.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued on Sunday, Wall Street Zen reports.

Several other analysts have also recently weighed in on the stock. Guggenheim raised their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. Leerink Partners increased their target price on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a "market perform" rating in a research note on Monday, August 17th. Royal Bank Of Canada increased their target price on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a "sector perform" rating in a research note on Friday, July 31st. Citigroup lifted their price target on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a "neutral" rating in a research note on Monday, August 3rd. Finally, Piper Sandler cut their price objective on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating for the company in a report on Thursday, July 9th. Fourteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $802.18.

Regeneron Pharmaceuticals Stock Down 0.6%

Shares of NASDAQ REGN opened at $784.85 on Friday. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average of $766.83 and a 200-day moving average of $720.73. The firm has a market capitalization of $80.81 billion, a price-to-earnings ratio of 19.40, a PEG ratio of 1.54 and a beta of 0.20. Regeneron Pharmaceuticals has a 12 month low of $541.00 and a 12 month high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts' consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same period last year, the firm posted $12.81 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was up 16.7% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals will post 44.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the sale, the director owned 1,703 shares of the company's stock, valued at approximately $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the firm's stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the transaction, the director owned 603 shares in the company, valued at $512,550. This represents a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,146 shares of company stock valued at $3,432,488 in the last 90 days. 6.97% of the stock is owned by insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in REGN. Tidal Investments LLC grew its position in shares of Regeneron Pharmaceuticals by 10.7% in the 2nd quarter. Tidal Investments LLC now owns 43,896 shares of the biopharmaceutical company's stock worth $27,371,000 after buying an additional 4,244 shares during the period. National Pension Service lifted its position in Regeneron Pharmaceuticals by 2.2% during the 2nd quarter. National Pension Service now owns 379,815 shares of the biopharmaceutical company's stock valued at $236,830,000 after acquiring an additional 8,264 shares during the period. Krensavage Asset Management LLC boosted its stake in Regeneron Pharmaceuticals by 50.0% during the second quarter. Krensavage Asset Management LLC now owns 6,000 shares of the biopharmaceutical company's stock worth $3,741,000 after acquiring an additional 2,000 shares in the last quarter. Engineers Gate Manager LP grew its holdings in Regeneron Pharmaceuticals by 4,309.4% in the second quarter. Engineers Gate Manager LP now owns 15,918 shares of the biopharmaceutical company's stock worth $9,926,000 after purchasing an additional 15,557 shares during the period. Finally, Cidel Asset Management Inc. grew its holdings in Regeneron Pharmaceuticals by 7.8% in the second quarter. Cidel Asset Management Inc. now owns 775 shares of the biopharmaceutical company's stock worth $483,000 after purchasing an additional 56 shares during the period. 83.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron's marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.